Literature DB >> 363332

Clinical pharmacokinetics of hypolipidaemic drugs.

R Gugler.   

Abstract

Mesh：

Substances：

Year:  1978        PMID： 363332     DOI： 10.2165/00003088-197803060-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  61 in total

1.  INITIAL DISTRIBUTION IN MICE OF 3H-LABELED NICOTINIC ACID STUDIED WITH AUTORADIOGRAPHY.

Authors:  L A CARLSON; A HANNGREN
Journal:  Life Sci (1962)       Date:  1964-08

2.  Metabolism of nicotinic acid and related compounds in man and rat.

Authors:  K K REDDI; E KODICEK
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

3.  Beta-sitosterolemia and xanthomatosis.

Authors:  R S Shulman; A K Bhattacharyya; W E Connor; D S Fredrickson
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

4.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

5.  Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs.

Authors:  A M Barrett; J M Thorp
Journal:  Br J Pharmacol Chemother       Date:  1968-02

Review 6.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-05       Impact factor: 91.245

7.  The influence of cholestyramine on thyroxine absorption.

Authors:  R C Northcutt; J N Stiel; J W Hollifield; E G Stant
Journal:  JAMA       Date:  1969-06-09       Impact factor: 56.272

Review 8.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man.

Authors:  J T Nicoloff; J C Low; J H Dussault; D A Fisher
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

10.  Urinary metabolites of 14 C-labeled thyroxine in man.

Authors:  C S Pittman; M W Buck; J B Chambers
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808
View more
  7 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].

Authors:  Tobias Kroon; Tania Baccega; Arne Olsén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2016-11-15       Impact factor: 5.922

Review 3.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

Review 4.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb

5.  Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.

Authors:  R Raedsch; J Plachky; N Wolf; G Simonis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

6.  Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.

Authors:  U Abshagen; S Spörl-Radun; J Marinow
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

7.  Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?

Authors:  H F Liu; M Vincent-Viry; M M Galteau; R Guéguen; J Magdalou; A Nicolas; P Leroy; G Siest
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.